| Caris Healthcare 5959 Shallowford Road Suite 551, Chattanooga, TN, 37421 | |
| (423) 899-4044 |
News Archive
The Phase I trial of ADXS11-001, the lead vaccine candidate of Advaxis, Inc. (OTCBB: ADXS), the company that pioneered the live, attenuated Listeria monocytogenes (Lm) vaccine, has shown thirty-six (36) month survival in three (3) of the thirteen (13) evaluable patients treated with Advaxis' therapeutic cancer vaccine, indicating the possibility of persistent immune protection.
A new discovery published in the April 2001 issue of Journal of Leukocyte Biology raises hope that new treatments for illnesses like Crohn's disease and ulcerative colitis are on the horizon.
Across the United States, many patients require insertion of emergency breathing tubes before arriving to a hospital, but emergency medicine researchers at the University of Pittsburgh School of Medicine have found that many paramedics - the highest level of prehospital providers - do not get enough clinical experience in this life-saving skill.
A Spanish researcher has collaborated on a mathematical analysis, recently published in the journal 'Science Translational Medicine', which concludes that joint therapy to counter HIV in patients who also have hepatitis C increases the chance of success in the fight against both infections. Between eight and nine million people worldwide simultaneously suffer from AIDS and hepatitis C.
MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, to address the major global problem of antibiotic resistance - announces that it has developed a stable intravenous (IV) formulation of MGB-BP-3, designed for the treatment of systemic susceptible and resistant Gram-positive hospital-acquired infections.
› Verified 7 days ago
| Name | Caris Healthcare |
|---|---|
| Location | 5959 Shallowford Road Suite 551, Chattanooga, Tennessee |
| Hospice ID | 441590 |
| Category | Freestanding Hospice |
| Ownership Type | Proprietary - Partnership |
| Profit Type | FOR PROFIT |
| SSA county code | 320 |
News Archive
The Phase I trial of ADXS11-001, the lead vaccine candidate of Advaxis, Inc. (OTCBB: ADXS), the company that pioneered the live, attenuated Listeria monocytogenes (Lm) vaccine, has shown thirty-six (36) month survival in three (3) of the thirteen (13) evaluable patients treated with Advaxis' therapeutic cancer vaccine, indicating the possibility of persistent immune protection.
A new discovery published in the April 2001 issue of Journal of Leukocyte Biology raises hope that new treatments for illnesses like Crohn's disease and ulcerative colitis are on the horizon.
Across the United States, many patients require insertion of emergency breathing tubes before arriving to a hospital, but emergency medicine researchers at the University of Pittsburgh School of Medicine have found that many paramedics - the highest level of prehospital providers - do not get enough clinical experience in this life-saving skill.
A Spanish researcher has collaborated on a mathematical analysis, recently published in the journal 'Science Translational Medicine', which concludes that joint therapy to counter HIV in patients who also have hepatitis C increases the chance of success in the fight against both infections. Between eight and nine million people worldwide simultaneously suffer from AIDS and hepatitis C.
MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, to address the major global problem of antibiotic resistance - announces that it has developed a stable intravenous (IV) formulation of MGB-BP-3, designed for the treatment of systemic susceptible and resistant Gram-positive hospital-acquired infections.
› Verified 7 days ago
| NPI Number | 1255330320 |
| Organization Name | Caris Healthcare, Lp |
| Address | 5959 Shallowford Rd Ste 551 Chattanooga, Tennessee, 37421 |
| Phone Number | (423)698-1488 |
News Archive
The Phase I trial of ADXS11-001, the lead vaccine candidate of Advaxis, Inc. (OTCBB: ADXS), the company that pioneered the live, attenuated Listeria monocytogenes (Lm) vaccine, has shown thirty-six (36) month survival in three (3) of the thirteen (13) evaluable patients treated with Advaxis' therapeutic cancer vaccine, indicating the possibility of persistent immune protection.
A new discovery published in the April 2001 issue of Journal of Leukocyte Biology raises hope that new treatments for illnesses like Crohn's disease and ulcerative colitis are on the horizon.
Across the United States, many patients require insertion of emergency breathing tubes before arriving to a hospital, but emergency medicine researchers at the University of Pittsburgh School of Medicine have found that many paramedics - the highest level of prehospital providers - do not get enough clinical experience in this life-saving skill.
A Spanish researcher has collaborated on a mathematical analysis, recently published in the journal 'Science Translational Medicine', which concludes that joint therapy to counter HIV in patients who also have hepatitis C increases the chance of success in the fight against both infections. Between eight and nine million people worldwide simultaneously suffer from AIDS and hepatitis C.
MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, to address the major global problem of antibiotic resistance - announces that it has developed a stable intravenous (IV) formulation of MGB-BP-3, designed for the treatment of systemic susceptible and resistant Gram-positive hospital-acquired infections.
› Verified 7 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 98.8 | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 99.4 | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | 100.0 | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | 92.8 | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | 99.4 | 97.3 |
| Patients who got timely treatment for shortness of breath | 97.0 | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | 98.6 | 93.3 |
News Archive
The Phase I trial of ADXS11-001, the lead vaccine candidate of Advaxis, Inc. (OTCBB: ADXS), the company that pioneered the live, attenuated Listeria monocytogenes (Lm) vaccine, has shown thirty-six (36) month survival in three (3) of the thirteen (13) evaluable patients treated with Advaxis' therapeutic cancer vaccine, indicating the possibility of persistent immune protection.
A new discovery published in the April 2001 issue of Journal of Leukocyte Biology raises hope that new treatments for illnesses like Crohn's disease and ulcerative colitis are on the horizon.
Across the United States, many patients require insertion of emergency breathing tubes before arriving to a hospital, but emergency medicine researchers at the University of Pittsburgh School of Medicine have found that many paramedics - the highest level of prehospital providers - do not get enough clinical experience in this life-saving skill.
A Spanish researcher has collaborated on a mathematical analysis, recently published in the journal 'Science Translational Medicine', which concludes that joint therapy to counter HIV in patients who also have hepatitis C increases the chance of success in the fight against both infections. Between eight and nine million people worldwide simultaneously suffer from AIDS and hepatitis C.
MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, to address the major global problem of antibiotic resistance - announces that it has developed a stable intravenous (IV) formulation of MGB-BP-3, designed for the treatment of systemic susceptible and resistant Gram-positive hospital-acquired infections.
› Verified 7 days ago
| Home Health Aides | 4 |
| Counselors | 1 |
| Medical Social Workers | 1 |
| Physicians | 0.5 |
| Registered Nurses | 4 |
| Other Personnel | 4 |
| Total Employees | 14.5 |
|---|
News Archive
The Phase I trial of ADXS11-001, the lead vaccine candidate of Advaxis, Inc. (OTCBB: ADXS), the company that pioneered the live, attenuated Listeria monocytogenes (Lm) vaccine, has shown thirty-six (36) month survival in three (3) of the thirteen (13) evaluable patients treated with Advaxis' therapeutic cancer vaccine, indicating the possibility of persistent immune protection.
A new discovery published in the April 2001 issue of Journal of Leukocyte Biology raises hope that new treatments for illnesses like Crohn's disease and ulcerative colitis are on the horizon.
Across the United States, many patients require insertion of emergency breathing tubes before arriving to a hospital, but emergency medicine researchers at the University of Pittsburgh School of Medicine have found that many paramedics - the highest level of prehospital providers - do not get enough clinical experience in this life-saving skill.
A Spanish researcher has collaborated on a mathematical analysis, recently published in the journal 'Science Translational Medicine', which concludes that joint therapy to counter HIV in patients who also have hepatitis C increases the chance of success in the fight against both infections. Between eight and nine million people worldwide simultaneously suffer from AIDS and hepatitis C.
MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, to address the major global problem of antibiotic resistance - announces that it has developed a stable intravenous (IV) formulation of MGB-BP-3, designed for the treatment of systemic susceptible and resistant Gram-positive hospital-acquired infections.
› Verified 7 days ago
| Others | 16 |
| Total Volunteers | 16 |
|---|
News Archive
The Phase I trial of ADXS11-001, the lead vaccine candidate of Advaxis, Inc. (OTCBB: ADXS), the company that pioneered the live, attenuated Listeria monocytogenes (Lm) vaccine, has shown thirty-six (36) month survival in three (3) of the thirteen (13) evaluable patients treated with Advaxis' therapeutic cancer vaccine, indicating the possibility of persistent immune protection.
A new discovery published in the April 2001 issue of Journal of Leukocyte Biology raises hope that new treatments for illnesses like Crohn's disease and ulcerative colitis are on the horizon.
Across the United States, many patients require insertion of emergency breathing tubes before arriving to a hospital, but emergency medicine researchers at the University of Pittsburgh School of Medicine have found that many paramedics - the highest level of prehospital providers - do not get enough clinical experience in this life-saving skill.
A Spanish researcher has collaborated on a mathematical analysis, recently published in the journal 'Science Translational Medicine', which concludes that joint therapy to counter HIV in patients who also have hepatitis C increases the chance of success in the fight against both infections. Between eight and nine million people worldwide simultaneously suffer from AIDS and hepatitis C.
MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, to address the major global problem of antibiotic resistance - announces that it has developed a stable intravenous (IV) formulation of MGB-BP-3, designed for the treatment of systemic susceptible and resistant Gram-positive hospital-acquired infections.
› Verified 7 days ago
| Hospice Of Chattanooga Inc Location: 4411 Oakwood Drive, Chattanooga, Tennessee, 37416 Phone: (423) 899-4044 |
| Amedisys Hospice, An Adventa Company Location: 7205 Lee Highway Suite B, Chattanooga, Tennessee, 37421 Phone: (423) 899-4044 |
| Avalon Hospice Location: 7625 Hamilton Park Drive Suite 19, Chattanooga, Tennessee, 37421 Phone: (423) 899-4044 |
| Caris Healthcare Location: 5959 Shallowford Road Suite 551, Chattanooga, Tennessee, 37421 Phone: (423) 899-4044 |